CLTC Antibody, FITC Conjugated is a fluorescently labeled monoclonal or polyclonal antibody targeting the clathrin heavy chain (CLTC), a 192 kDa protein critical for forming clathrin-coated vesicles involved in intracellular trafficking . FITC conjugation enables direct visualization under fluorescence microscopy or flow cytometry, bypassing the need for secondary antibodies .
Protocol: Cells are fixed, permeabilized, and incubated with CLTC-FITC antibody (1:50–1:500 dilution) . Example: Detection in HepG2 and HeLa cells showed distinct vesicular staining patterns .
Advantage: Direct conjugation reduces experimental steps and background noise .
Intracellular Staining: Permeabilized HepG2 cells treated with 0.8 µg/10⁶ cells of CL488-26523 exhibited specific CLTC signal, validated via isotype controls .
Tissue Staining: CLTC-FITC antibodies (e.g., M03134-2) detected CLTC in paraffin-embedded pancreatic cancer, renal carcinoma, and tonsil tissues .
Viral Entry Mechanisms: CLTC knockout reduced but did not abolish SFTSV infection, implicating clathrin-mediated endocytosis as a primary viral entry route .
Drug Delivery Studies: FITC-conjugated probes (e.g., cisplatin-loaded exosomes) demonstrated clathrin-independent trafficking, highlighting alternative pathways .